Rapport Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Rapport Therapeutics, Inc. (RAPP) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022
Period EndingDec 2024Dec 2023Dec 2022
Operating Activities
Net Income-78.31-34.79-11.62
Depreciation & Amortization0.840.110.02
Stock Based Compensation10.243.530.61
Change in Working Capital-2.422.651.62
Change in Accounts Payable-0.350.861.58
Change in Other Working Capital-2.071.800.05
Other Operating Activities4.821.390.38
Net Cash from Operating Activities-64.83-27.18-3.54
Investing Activities
Capital Expenditures-2.41-1.64-0.31
Purchases of Investments-380.74-77.220.00
Sales/Maturities of Investments209.800.00-5.45
Other Investing Activities3.210.000.00
Net Cash from Investing Activities-170.14-78.86-5.76
Financing Activities
Common Stock Issued157.710.050.03
Common Stock Repurchased0.000.000.00
Other Financing Activities63.92-0.13-0.11
Net Cash from Financing Activities221.63145.1443.29
Summary
Net Change in Cash-13.3439.1033.99
Cash at Beginning of Period70.2531.160.00
Cash at End of Period56.9170.250.00
Free Cash Flow-67.23-28.82-3.85